Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 17;7(6):701–710. doi: 10.1242/dmm.014548

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 1. — Early HOE-140 treatment protects mice from the development of FSGS. Four days after the injection of 10 mg of Adriamycin (ADM) per kg of bodyweight, Balb/c mice were killed. HOE-140 treatment protected mice from proteinuria (A) and albuminuria (B). HOE-140 also prevented the downregulation of the mRNAs encoding the podocyte proteins WT-1 (C) and podocin (NPHS-2) (D); however, HOE-140 did not affect the levels of nephrin (NPHS-1) (E) and α-actinin-4 (ACTN-4) (F) mRNA that were induced by ADM injection. The treatment also prevented the upregulation of mRNAs for the pro-inflammatory (IL-1β and B1RBK) (G,H) and pro-fibrotic markers TGF-β (I), PAI-1 (J) and CTGF (K). Expression of the mRNAs were normalized to that of hypoxanthine guanine phosphoribosyl transferase (HPRT). *P<0.05 compared with that of control mice, ^#P<0.05 compared with that of mice treated with only ADM. Five animals were used per study group.